Who are alpha-blocker and NSAID's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-blocker-and-nsaid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

alpha-blocker and NSAID — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

alpha-blocker and NSAID (alpha-blocker and NSAID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-blocker and NSAID combination. Area: Urology.

marketed Alpha-blocker and NSAID combination Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes Urology Small molecule Live · refreshed every 30 min

Target snapshot

alpha-blocker and NSAID (alpha-blocker and NSAID) — Samsung Medical Center. This combination blocks alpha-adrenergic receptors to relax smooth muscle in the urinary tract while inhibiting cyclooxygenase enzymes to reduce inflammation and pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
alpha-blocker and NSAID TARGET	alpha-blocker and NSAID	Samsung Medical Center	marketed	Alpha-blocker and NSAID combination	Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-blocker and NSAID combination class)

Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alpha-blocker and NSAID — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-blocker-and-nsaid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing